Reducing the Burden of Breast Cancer for Australian Women and Their Families

Association analysis identifies 65 new breast cancer risk loci

K Michailidou, S Lindström, J Dennis, J Beesley, S Hui, S Kar, A Lemaçon, P Soucy, D Glubb, A Rostamianfar, MK Bolla, Q Wang, J Tyrer, E Dicks, A Lee, Z Wang, J Allen, R Keeman, U Eilber, JD French

2017-11-02

Breast cancer risk is influenced by rare coding variants in susceptibility genes, such as BRCA1, and many common, mostly non-codin..

Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancer

YC Lee, M Bressel, P Grant, P Russell, C Smith, S Picken, S Camm, BE Kiely, RL Milne, SA McLachlan, M Hickey, ML Friedlander, JL Hopper, KA Phillips

2017-10-01

Objectives: The quality of risk-reducing salpingo-oophorectomy (RRSO) performed in Australasian women was previously reported to b..

Early detection of ovarian cancer using the risk of ovarian cancer algorithm with frequent CA125 testing in women at increased familial risk – Combined results from two screening trials

SJ Skates, MH Greene, SS Buys, PL Mai, P Brown, M Piedmonte, G Rodriguez, JO Schorge, M Sherman, MB Daly, T Rutherford, WR Brewster, DM O'Malley, E Partridge, J Boggess, CW Drescher, C Isaacs, A Berchuck, S Domchek, SA Davidson

2017-07-15

Purpose: Women at familial/genetic ovarian cancer risk often undergo screening despite unproven efficacy. Research suggests each w..

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

CM Phelan, KB Kuchenbaecker, JP Tyrer, SP Kar, K Lawrenson, SJ Winham, J Dennis, A Pirie, MJ Riggan, G Chornokur, MA Earp, PC Lyra, JM Lee, S Coetzee, J Beesley, L McGuffog, P Soucy, E Dicks, A Lee, D Barrowdale

2017-05-01

To identify common alleles associated with different histotypes of epithelial ovarian cancer (EOC), we pooled data from multiple g..

Debated role of ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in women with cancer

M Lambertini, T Falcone, JM Unger, KA Phillips, L Del Mastro, HCF Moore

2017-03-01

Women's preferences for contralateral prophylactic mastectomy following unilateral breast cancer: What risk-reduction makes it worthwhile?

S Tesson, I Richards, D Porter, KA Phillips, N Rankin, D Costa, T Musiello, M Marven, P Butow

2017-02-01

Objectives Contralateral prophylactic mastectomy (CPM) reduces the risk of contralateral breast cancer (BC) following unilateral B..

Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab

H Li, B Feng, A Miron, X Chen, J Beesley, E Bimeh, D Barrowdale, EM John, MB Daly, IL Andrulis, SS Buys, P Kraft, H Thorne, G Chenevix-Trench, MC Southey, AC Antoniou, PA James, MB Terry, KA Phillips, JL Hopper

2017-01-01

Purpose:This study examined the utility of sets of single-nucleotide polymorphisms (SNPs) in familial but non-BRCA-Associated brea..

Contralateral prophylactic mastectomy (CPM): A systematic review of patient reported factors and psychological predictors influencing choice and satisfaction

B Ager, P Butow, J Jansen, KA Phillips, D Porter, N Rankin, T Musiello, F Boyle, N Zdenkowski, A Skandarajah, C Saunders, P Sundaresan, R De, A Lourenco

2016-08-01

Objective: Conduct a systematic review of quantitative and qualitative studies exploring patient reported factors and psychologica..

Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent

Y Guo, S Warren Andersen, XO Shu, K Michailidou, MK Bolla, Q Wang, M Garcia-Closas, RL Milne, MK Schmidt, J Chang-Claude, A Dunning, SE Bojesen, H Ahsan, K Aittomäki, IL Andrulis, H Anton-Culver, V Arndt, MW Beckmann, A Beeghly-Fadiel, J Benitez

2016-08-01

Background: Observational epidemiological studies have shown that high body mass index (BMI) is associated with a reduced risk of ..

Cohort profile: The breast cancer prospective family study cohort (ProF-SC)

MB Terry, KA Phillips, MB Daly, EM John, IL Andrulis, SS Buys, DE Goldgar, JA Knight, AS Whittemore, WK Chung, C Apicella, JL Hopper

2016-06-01

Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations

KA Phillips, IM Collins, RL Milne, SA McLachlan, M Friedlander, M Hickey, C Stern, JL Hopper, R Fisher, G Kannemeyer, S Picken, CD Smith, TW Kelsey, RA Anderson

2016-05-01

STUDY QUESTION: Do women with BRCA1 or BRCA2 mutations have reduced ovarian reserve, as measured by circulating anti-Müllerian hor..

Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry

Z Zhao, W Wen, K Michailidou, MK Bolla, Q Wang, B Zhang, J Long, XO Shu, MK Schmidt, RL Milne, M García-Closas, J Chang-Claude, S Lindstrom, SE Bojesen, H Ahsan, K Aittomäki, IL Andrulis, H Anton-Culver, V Arndt, MW Beckmann

2016-05-01

Purpose: Type 2 diabetes (T2D) has been reported to be associated with an elevated risk of breast cancer. It is unclear, however, ..

No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer

A Hollestelle, FH Van Der Baan, A Berchuck, SE Johnatty, KK Aben, BA Agnarsson, K Aittomäki, E Alducci, IL Andrulis, H Anton-Culver, NN Antonenkova, AC Antoniou, C Apicella, V Arndt, N Arnold, BK Arun, B Arver, A Ashworth, L Baglietto, R Balleine

2016-05-01

Objective Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3′ UTR microR..

Women's preferences for contralateral prophylactic mastectomy: An investigation using protection motivation theory

S Tesson, I Richards, D Porter, KA Phillips, N Rankin, T Musiello, M Marven, P Butow

2016-05-01

Objective: Most women diagnosed with unilateral breast cancer without BRCA1 or BRCA2 mutations are at low risk of contralateral br..

Adjuvant ovarian function suppression and cognitive function in women with breast cancer

KA Phillips, MM Regan, K Ribi, PA Francis, F Puglisi, M Bellet, S Spazzapan, P Karlsson, DR Budman, K Zaman, EA Abdi, SM Domchek, Y Feng, KN Price, AS Coates, RD Gelber, P Maruff, F Boyle, JF Forbes, T Ahles

2016-04-26

Background:To examine the effect on cognitive function of adjuvant ovarian function suppression (OFS) for breast cancer.Methods:Th..

Predicting women's intentions for contralateral prophylactic mastectomy: An application of an extended theory of planned behaviour

I Richards, S Tesson, D Porter, KA Phillips, N Rankin, T Musiello, M Marven, P Butow

2016-04-01

Purpose: Most women with unilateral breast cancer (BC) without BRCA1/2 gene mutations are at low risk of contralateral breast canc..

Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170

AM Dunning, K Michailidou, KB Kuchenbaecker, D Thompson, JD French, J Beesley, CS Healey, S Kar, KA Pooley, E Lopez-Knowles, E Dicks, D Barrowdale, NA Sinnott-Armstrong, RC Sallari, KM Hillman, S Kaufmann, H Sivakumaran, MM Marjaneh, JS Lee, M Hills

2016-03-29

We analyzed 3,872 common genetic variants across the ESR1 locus (encoding estrogen receptor α) in 118,816 subjects from three inte..

Breast cancer risk prediction using clinical models and 77 independent risk-associated SNPs for women aged under 50 years: Australian breast cancer family registry

GS Dite, RJ Macinnis, A Bickerstaffe, JG Dowty, R Allman, C Apicella, RL Milne, H Tsimiklis, KA Phillips, GG Giles, MB Terry, MC Southey, JL Hopper

2016-02-01

Background: The extent to which clinical breast cancer risk prediction models can be improved by including information on known su..

iPrevent®: a tailored, web-based, decision support tool for breast cancer risk assessment and management

IM Collins, A Bickerstaffe, T Ranaweera, S Maddumarachchi, L Keogh, J Emery, GB Mann, P Butow, P Weideman, E Steel, A Trainer, M Bressel, JL Hopper, J Cuzick, AC Antoniou, KA Phillips

2016-02-01

We aimed to develop a user-centered, web-based, decision support tool for breast cancer risk assessment and personalized risk mana..

Transitioning to routine breast cancer risk assessment and management in primary care: What can we learn from cardiovascular disease?

KA Phillips, EJ Steel, I Collins, J Emery, M Pirotta, GB Mann, P Butow, JL Hopper, A Trainer, J Moreton, AC Antoniou, J Cuzick, L Keogh

2016-01-01

To capitalise on advances in breast cancer prevention, all women would need to have their breast cancer risk formally assessed. Wi..

Intuition versus cognition: a qualitative exploration of how women understand and manage their increased breast cancer risk

Louise Heiniger, Phyllis N Butow, Margaret Charles, Melanie A Price

2015-10-01

Risk comprehension in individuals at increased familial risk of cancer is suboptimal and little is known about how risk is underst..

Identification of novel genetic markers of breast cancer survival

Q Guo, MK Schmidt, P Kraft, S Canisius, C Chen, S Khan, J Tyrer, MK Bolla, Q Wang, J Dennis, K Michailidou, M Lush, S Kar, J Beesley, AM Dunning, M Shah, K Czene, H Darabi, M Eriksson, D Lambrechts

2015-05-01

Background: Survival after a diagnosis of breast cancer varies considerably between patients, and some of this variation may be be..

Common germline polymorphisms associated with breast cancer-specific survival

A Pirie, Q Guo, P Kraft, S Canisius, DM Eccles, N Rahman, H Nevanlinna, C Chen, S Khan, J Tyrer, MK Bolla, Q Wang, J Dennis, K Michailidou, M Lush, AM Dunning, M Shah, K Czene, H Darabi, M Eriksson

2015-04-22

© 2015 Pirie et al. Introduction: Previous studies have identified common germline variants nominally associated with breast cance..

Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer

TR Rebbeck, N Mitra, F Wan, OM Sinilnikova, S Healey, L McGuffog, G Chenevix-Trench, DF Easton, AC Antoniou, KL Nathanson, Y Laitman, A Kushnir, S Paluch-Shimon, R Berger, J Zidan, E Friedman, H Ehrencrona, M Stenmark-Askmalm, Z Einbeigi, N Loman

2015-04-07

Importance: Limited information about the relationship between specific mutations in BRCA1 or BRCA2 (BRCA1/2) and cancer risk exis..

Assessing associations between the AURKAHMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers

I Blanco, K Kuchenbaecker, D Cuadras, X Wang, D Barrowdale, GR De Garibay, P Librado, A Sánchez-Gracia, J Rozas, N Bonifaci, L McGuffog, VS Pankratz, A Islam, F Mateo, A Berenguer, A Petit, I Català, J Brunet, L Feliubadaló, E Tornero

2015-04-01

While interplay between BRCA1 and AURKA-RHAMM-TPX2-TUBG1 regulates mammary epithelial polarization, common genetic variation in HM..

Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy

HCF Moore, JM Unger, KA Phillips, F Boyle, E Hitre, D Porter, PA Francis, LJ Goldstein, HL Gomez, CS Vallejos, AH Partridge, SR Dakhil, AA Garcia, J Gralow, JM Lombard, JF Forbes, S Martino, WE Barlow, CJ Fabian, L Minasian

2015-03-05

BACKGROUND Ovarian failure is a common toxic effect of chemotherapy. Studies of the use of gonadotropin- releasing hormone (GnRH) ..

Clinical management of women at high risk of breast cancer

M Wuttke, KA Phillips

2015-02-13

PURPOSE OF REVIEW: This article reviews the evidence that underpins breast cancer screening and prevention strategies for women at..

Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy

J Lei, A Rudolph, KB Moysich, S Rafiq, S Behrens, EL Goode, PPD Pharoah, P Seibold, PA Fasching, IL Andrulis, VN Kristensen, FJ Couch, U Hamann, MJ Hooning, H Nevanlinna, U Eilber, MK Bolla, J Dennis, Q Wang, A Lindblom

2015-02-10

Introduction: Tumor lymphocyte infiltration is associated with clinical response to chemotherapy in estrogen receptor (ER) negativ..

Women’s preferences for selective estrogen reuptake modulators: an investigation using the time trade-off technique

AF Ralph, B Ager, ML Bell, IM Collins, L Andrews, K Tucker, N O’Reilly, KA Phillips, P Butow

2014-12-01

Purpose: Selective Estrogen Receptor Modulators (SERMs) reduce the risk of breast cancer for women at increased risk by 38%. Howev..

Abortion and breast cancer risk for Australian women

KA Phillips, FJ Bruinsma, RL Milne

2014-10-06

Assessing and managing breast cancer risk: Clinicians' current practice and future needs

IM Collins, E Steel, GB Mann, JD Emery, A Bickerstaffe, A Trainer, P Butow, M Pirotta, AC Antoniou, J Cuzick, J Hopper, KA Phillips, LA Keogh

2014-10-01

Decision support tools for the assessment and management of breast cancer risk may improve uptake of prevention strategies. End-us..

2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy

J Li, LS Lindström, JN Foo, S Rafiq, MK Schmidt, PDP Pharoah, K Michailidou, J Dennis, MK Bolla, Q Wang, LJ Van'T Veer, S Cornelissen, E Rutgers, MC Southey, C Apicella, GS Dite, JL Hopper, PA Fasching, L Haeberle, AB Ekici

2014-06-17

Large population-based registry studies have shown that breast cancer prognosis is inherited. Here we analyse single-nucleotide po..

Misperceptions of ovarian cancer risk in women at increased risk for hereditary ovarian cancer

B Meiser, MA Price, PN Butow, B Rahman, K Tucker, B Cheah, A Bickerstaffe, J Hopper, KA Phillips, B Bennett, C Tennant, RL Milne, P Weideman, L Stanhope, S Picken, ML Friedlander, D Goldgar

2014-06-01

This study assessed the sociodemographic, medical and psychological predictors of accuracy of perceived risk in women at increased..

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): An international, double-blind, randomised placebo-controlled trial

J Cuzick, I Sestak, JF Forbes, M Dowsett, J Knox, S Cawthorn, C Saunders, N Roche, RE Mansel, G Von Minckwitz, B Bonanni, T Palva, A Howell

2014-01-01

Background Aromatase inhibitors eff ectively prevent breast cancer recurrence and development of new contralateral tumours in post..

Women's preferences for selective estrogen reuptake modulators: An investigation using protection motivation theory

AF Ralph, B Ager, ML Bell, IM Collins, L Andrews, K Tucker, KA Phillips, P Butow

2014-01-01

Objective: Selective estrogen receptor modulators (SERMs) reduce breast cancer risk by 38%. However, uptake is low and the reasons..

Do BRCA1 and BRCA2 mutation carriers have earlier natural menopause than their noncarrier relatives? Results from the Kathleen Cuningham foundation consortium for research into familial breast cancer

IM Collins, RL Milne, SA McLachlan, M Friedlander, M Hickey, PC Weideman, KE Birch, JL Hopper, KA Phillips

2013-11-01

Purpose: Limited data suggest that germline BRCA1 mutations are associated with occult primary ovarian insufficiency and that BRCA..

Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers

IM Collins, RL Milne, PC Weideman, SA McLachlan, ML Friedlander, K Cuningham, JL Hopper, KA Phillips

2013-11-01

Objective: To estimate the prevalence of the use of cancer risk-reducing measures among Australian BRCA1 and BRCA2 mutation carrie..

Prospective validation of the breast cancer risk prediction model BOADICEA and a batch-mode version BOADICEACentre

RJ MacInnis, A Bickerstaffe, C Apicella, GS Dite, JG Dowty, K Aujard, KA Phillips, P Weideman, A Lee, MB Terry, GG Giles, MC Southey, AC Antoniou, JL Hopper

2013-09-01

Background:Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) is a risk prediction algor..

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers

KA Phillips, RL Milne, MA Rookus, MB Daly, AC Antoniou, S Peock, D Frost, DF Easton, S Ellis, ML Friedlander, SS Buys, N Andrieu, C Noguès, D Stoppa-Lyonnet, V Bonadona, P Pujol, SA McLachlan, EM John, MJ Hooning, C Seynaeve

2013-09-01

Purpose To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is associated with reduced contralateral breast c..

Using SNP genotypes to improve the discrimination of a simple breast cancer risk prediction model

GS Dite, M Mahmoodi, A Bickerstaffe, F Hammet, RJ Macinnis, H Tsimiklis, JG Dowty, C Apicella, KA Phillips, GG Giles, MC Southey, JL Hopper

2013-06-01

It has been shown that, for women aged 50 years or older, the discriminatory accuracy of the Breast Cancer Risk Prediction Tool (B..

Psychosocial factors and uptake of risk-reducing salpingo-oophorectomy in women at high risk for ovarian cancer

B Meiser, MA Price, PN Butow, J Karatas, J Wilson, L Heiniger, B Baylock, M Charles, SA McLachlan, KA Phillips

2013-03-01

Bilateral risk-reducing salpingo-oophorectomy (RRSO) has been shown to significantly reduce the risk of ovarian cancer. This study..